OTCMKTS:LBTSF - Almirall Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$15.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Almirall Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LBTSF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LBTSF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Almirall in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.00.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Almirall. This rating has held steady since April 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/29/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
i
10/6/2020Credit Suisse GroupReiterated RatingNeutral
i
7/21/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral
i
7/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
i
5/8/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy
i
5/2/2019Jefferies Financial GroupUpgradeHold ➝ Buy
i
1/11/2019BNP ParibasUpgradeUnderperform ➝ Neutral
i
(Data available from 4/17/2016 forward)
Almirall logo
Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $15.00
$15.00
$15.00

50 Day Range

MA: $13.79
$12.40
$15.20

52 Week Range

Now: $15.00
$14.00
$15.20

Volume

N/A

Average Volume

1,150 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Almirall?

The following Wall Street research analysts have issued stock ratings on Almirall in the last year: Credit Suisse Group AG, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for LBTSF.

What is the current price target for Almirall?

0 Wall Street analysts have set twelve-month price targets for Almirall in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Almirall in the next year.
View the latest price targets for LBTSF.

What is the current consensus analyst rating for Almirall?

Almirall currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LBTSF will outperform the market and that investors should add to their positions of Almirall.
View the latest ratings for LBTSF.

What other companies compete with Almirall?

How do I contact Almirall's investor relations team?

The company's listed phone number is 34 93 291 30 00. The official website for Almirall is www.almirall.com.